Influenza virus vaccine liposomal intranasal - Berna Biotech

Drug Profile

Influenza virus vaccine liposomal intranasal - Berna Biotech

Alternative Names: Nasalflu

Latest Information Update: 13 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berna Biotech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Influenza virus infections

Most Recent Events

  • 06 Jun 2002 Discontinued - Preregistration for Influenza virus infections in Germany (Intranasal)
  • 14 Sep 2001 Withdrawn for Influenza virus infections in Switzerland (Intranasal)
  • 24 Jul 2001 The Swiss Serum and Vaccine Institute Berne is now called Berna Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top